NoNO-42 Trial in Acute Ischemic Stroke Patients Selected for Thrombolysis with or Without Endovascular Thrombectomy

NoNO Inc.

Status and phase: Enrolling; Phase 2

Conditions: Acute Ischemic Stroke

Treatments: Drug: NoNO-42; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT06403267

NoNO42-02 (ACT-42)

Details and patient eligibility

About

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632).

This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial.

A total of up to 600 male and female participants aged ≥ 45 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 3 hours of stroke onset/last known well.

Full description

Because AIS is a medical emergency, the trial is designed to enable the administration of standard-of-care treatments in order to save the life of the person concerned, restore good health and alleviate suffering.

A total of up to 600 male and female participants aged ≥ 45 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 3 hours of stroke onset/last known well. Randomization will be 1:1 drug/placebo. Randomization will be stratified by large vessel occlusion (LVO) (yes/no) and a minimization algorithm to minimize the contribution of imbalances in baseline factors (age, sex, baseline NIHSS score). The design is adaptive with prospective rules for adaptive enrichment, in which enrollment may be restricted to participants without an LVO. LVO is defined as an occlusion of the intracranial ICA, M1 or proximal M2.

Randomized participants will be given a single, 2.6 mg/kg 20-minute intravenous dose of NoNO-42 or placebo (placebo comprising normal saline infusion only) with a target start time of less than 10 minutes from randomization.

All participants will be followed for 90 days (or until death if prior to 90 days) for efficacy and 30 days for safety. The end of the trial is defined as the date that all participants have completed their Day 90 contact.

Enrollment: 600 estimated patients

Sex: All

Ages: 45 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Acute ischemic stroke (AIS) selected for thrombolysis with or without EVT.
2. Onset (last-known-well) time to randomization time within 3 hours.
3. Ages ≥ 45 to ≤ 90 years.
4. Disabling stroke defined as a baseline National Institutes of Health Stroke Score (NIHSS) > 5.
5. Confirmed symptomatic anterior circulation intracranial occlusion. Tandem extracranial carotid and intracranial occlusions are permitted.
6. Pre-stroke independent functional status in activities of daily living as judged by the enrolling physician. Patient must be living without requiring nursing care.
7. Consent process completed as per national laws and regulation and the applicable ethics committee requirements.

Exclusion criteria

1. Large extent early ischemic changes/infarct in the ischemic territory on qualifying imaging, defined as early ischemic changes on NCCT.
2. Any intracranial hemorrhage on qualifying imaging.
3. Unlikely to initiate study drug/placebo administration before arterial puncture in those selected for EVT.
4. Estimated or known weight > 115 kg (253 lbs).
5. Known/suspected pregnancy and/or lactation.
6. Systolic blood pressure < 90 mmHg
7. Known prior receipt of NoNO-42 for any reason, including prior enrolment in this trial.
8. Severe comorbid illness with life expectancy less than 90 days, or likely to prevent completing 90-day follow-up.
9. Long term care facility resident or prisoner
10. Participation in another clinical trial investigating a drug or medical device or a neuro-interventional or surgical procedure that is not considered as standard care in the 30 days preceding trial enrolment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

600 participants in 2 patient groups, including a placebo group

NoNO-42

Active Comparator group

Description:

Randomized participants will be given a single, 2.6 mg/kg 20-minute intravenous dose of NoNO-42 with a target start time of less than 10 minutes from randomization.

Treatment:

Drug: NoNO-42

Placebo

Placebo Comparator group

Description:

Randomized participants will be given a single 20-minute intravenous dose of placebo (comprising normal saline infusion only) with a target start time of less than 10 minutes from randomization.

Treatment:

Drug: Placebo